Evolution of acute myelogenous leukemia stem cell properties after treatment and progression
Tzu‐Chieh Ho(University School), Michael W. Becker(Helios Hospital Berlin-Buch), Jason H. Mendler(University of Rochester Medicine), Jennifer D. Morrissette(Hospital of the University of Pennsylvania), Mark W. LaMere(University of Rochester Medicine), Eunice S. Wang(Roswell Park Comprehensive Cancer Center), Jianhua Zhao(Southwest Petroleum University), Meir Wetzler, Brett M. Stevens(University of Colorado Anschutz Medical Campus), Jason R. Myers(University of Rochester), Mónica L. Guzmán(NewYork–Presbyterian Hospital), Jane L. Liesveld(Strong Memorial Hospital), John M. Ashton(University of Rochester), Craig T. Jordan(University of Colorado Anschutz Medical Campus), Kristen M. O’Dwyer(University of Rochester Medical Center)
Cited by 236
Related Papers
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
<i>IDH1</i> and <i>IDH2</i> Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
|Journal of Clinical Oncology|2010|764
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2021|714
The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells
|Blood|2005|675
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2017|655